858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing small molecule therapeutics targeting oncology and immunology. Their lead program, ETX-19477, is a PARG inhibitor currently in Phase 1 clinical trials for advanced solid tumors. The company leverages decades of drug discovery experience from its founders.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $50M
Date: 26-Sep-2024
Investors: Avidity Partners, Insight Partners, Mirae Asset Capital, Alexandria Venture Investments, Versant Ventures, NEA, Logos Capital
Markets: Biotechnology, Oncology, Immunology, Drug Discovery
HQ: San Diego, California, United States
Founded: 2019
Website: https://www.8five8tx.com/
LinkedIn: https://www.linkedin.com/company/858-therapeutics
Crunchbase: https://www.crunchbase.com/organization/858-therapeutics
Leave a Comment
Comments
No comments yet.